OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Weinberg on Treating Patients with NTRK Fusions in NSCLC

April 29th 2022

Frank Weinberg, MD, PhD, discusses the treatment options in non–small cell lung cancer harboring NTRK fusions.

Dr. Maron on Sequencing Considerations in the Frontline Treatment of GI Cancers

April 28th 2022

Steven Maron, MD, MSc, discusses sequencing considerations in the frontline treatment of gastrointestinal cancers.

Dr. Khan on Racial Disparities with Patient Surgical Outcomes in GI Tract Cancer

April 28th 2022

Sajid A Khan MD, FACS, FSSO, discusses racial disparities with patient surgical outcomes in gastrointestinal tract cancer.

Dr. Edington on the Utilization of TVEC Therapy in Melanoma

April 28th 2022

Howard D. Edington, MD, discusses the use of talimogene laherparepvec in melanoma.

Dr. Taylor on Findings from a Genomic Analysis on BTK Inhibitors in CLL

April 27th 2022

Justin W. Taylor, MD, discusses findings from a genomic analysis on BTK inhibitors in chronic lymphocytic leukemia.

Dr. Lee on the Importance of Sequencing in Precision Medicine

April 27th 2022

Kelvin P. Lee, MD, discusses the importance of sequencing in precision medicine.

Dr. Kirkwood on the Use of Ipilimumab/Nivolumab in Melanoma With Brain Metastases

April 26th 2022

John M. Kirkwood, MD, discusses the utilization of ipilimumab and nivolumab in patients with melanoma with brain metastases.

Dr. Armstrong on Updated Results of the ARCHES Trial in mHSPC

April 26th 2022

Andrew J. Armstrong, MD, MSc, discusses updated results from the phase 3 ARCHES trial in metastatic hormone-sensitive prostate cancer.

Dr. Huang on Research in ALK+ NSCLC

April 26th 2022

Chao H. Huang, MD, FACP, discusses ongoing research around the use of ALK inhibitors for non–small cell lung cancer.

Dr. Kalinsky on Strategies to Prevent Recurrence in Early Breast Cancer

April 26th 2022

Kevin Kalinsky, MD, MS, discusses the potential benefits of chemotherapy in preventing disease recurrence in premenopausal patients with breast cancer.

Dr. DeCesaris on Classical vs Contemporary Indications for Radiation in Breast Cancer

April 26th 2022

Cristina DeCesaris, MD, discusses classical indications for breast cancer radiation and how these methods are being contextualized in the contemporary treatment era.

Dr. Bezerra on Barriers to Enrollment for Clinical Trials in B-Cell NHL

April 26th 2022

Evandro D. Bezerra, MD, discusses barriers to enrollment in clinical trials for patients with aggressive B-cell non-Hodgkin lymphoma who have progressed on anti-CD19 CAR T-cell therapy.

Dr. Blay on the Exploration of BI 907828 in Patients With Sarcoma

April 25th 2022

Jean-Yves Blay, MD, discusses the exploration of BI 907828 in patients with sarcoma.

Dr. Verstovsek on the Mechanism of Action of Momelotinib in Myelofibrosis

April 25th 2022

Srdan Verstovsek, MD, PhD, discusses the mechanisms of action of momelotinib in myelofibrosis.

Dr. Akbar on the Efficacy of Monoclonal Antibodies Across Various Trials in R/R ALL

April 25th 2022

Usman Ali Akbar, MD, discusses the systematic review of the efficacy of monoclonal antibodies in adult patients with relapsed/refractory acute lymphoblastic leukemia.

Dr. Abid on Adaptive Lymphodepletion in CAR T-Cell Recipients in R/R B-Cell NHL

April 25th 2022

Muhammad Bilal Abid, MD, MRCP, discusses the impact of adaptive lymphodepletion in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma who received CAR T-cell therapy.

Dr. Dahiya on Long-Term, Real-World Follow-Up of Axi-Cel in LBCL

April 25th 2022

Saurabh Dahiya, MBBS, discusses real-world data observed from a long-term follow-up of axicabtagene ciloleucel in large B-cell lymphoma.

Dr. Shadman on the Efficacy of MB-106 in Relapsed/Refractory NHL and CLL

April 25th 2022

Mazyar Shadman, MD, MPH, discusses the efficacy of MB-106, a CD20-targeted CAR T-cell therapy in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Dr. Riedell on the Examination of Axi-Cel Therapy in High-Risk LBCL

April 25th 2022

Peter Riedell, MD, discusses the use of axicabtagene ciloleucel in high-risk large B-cell lymphoma, as evaluated on the phase 2 ZUMA-12 trial.

Dr. Khushalani on the Mechanism of Action of RP1 in Cancer Care

April 22nd 2022

Nikhil Khushalani, MD, discusses the mechanism of action vusolimogene oderparepvec in cancer care.